WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Health Services Advisory Group, Inc. (HSAG)
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Webinar
AI
Iktos, Kadmon | May 19, 2021
Iktos, a company specializing in Artificial Intelligence for new drug design, announced today that it has signed a Research Collaboration Agreement with Kadmon, a clinical-stage biopharmaceutical company based in New York, USA, under which Iktos' generative modeling artificial intelligence (AI) technology will be used to allow the rapid and cost-effective design of novel drug candidates. Iktos will use its de novo structure-based generative modeling technologies to find novel compounds that ...
FierceBiotech | February 06, 2020
Just months after collecting $90 million to support the launch of its compact DNA sequencing hardware, GenapSys has raised another $75 million to finance its global expansion with its eyes set on the Asia-Pacific market and the expanding coronavirus outbreak. The company’s high-throughput sequencer—which sits on a tabletop and weighs less than 10 pounds—is being launched in South Korea, Singapore, Japan and China as part of more than 25 recently inked distribution deals....
Industrial Impact
Cellics Therapeutics | September 13, 2022
Cellics Therapeutics, Inc., a biotechnology company pioneering Cellular Nanoparticle platform technology for drug development and delivery, announced today that the company has appointed Paul Daruwala as the company's president and chief executive officer, effective on October 1st, 2022. With 30 years of experience in biotech drug development, Daruwala brings a depth of vision, as well as start-up and operational experience to Cellics. "With our Cellular Nanoparticle plat...
Cell and Gene Therapy
Specific Biologics Inc. | December 08, 2021
Specific Biologics Inc. an early-stage biotechnology company developing novel gene editing technologies, announced that it will receive more than US$527,000 to support the preclinical development of its Dualase™ gene editing platform to target a set of cystic fibrosis -causing nonsense mutations where patients currently have fewer therapeutic options available. "Incredible advancements in the treatment of cystic fibrosis have been made since the id...
infographic
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE